This article is more than 5 years old. Information may no longer be current.
Mitek Sports Medicine introduces hyaluronan treatment, PRP system
Click Here to Manage Email Alerts
Mitek Sports Medicine launched Monovisc High Molecular Weight Hyaluronan and the PEAK Platelet-Rich Plasma System at the American Orthopaedic Society for Sports Medicine Annual Meeting.
“Our goal with these single- and multiple-injection products, and our new PRP system, is to provide a range of options across the sports medicine patient continuum of care that help return patients to the activities they enjoy as quickly as possible,” Ian Lawson, worldwide president of Mitek Sports Medicine, stated in a company press release.
Monovisc is a single-injection hyaluronan treatment that can provide up to 6 months of pain relief and helps restore joint mobility in patients with knee osteoarthritis. It is injected directly into the knee to help replace the naturally occurring hyaluronan and to cushion, protect and lubricate the knee joint. Monovisc is for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, such as acetaminophen.
The PEAK Platelet-Rich Plasma (PRP) System separates PRP from a sample of a patient’s own blood. According to the release, the device produces 3 mL of high-quality PRP from 27 mL of whole blood in 2.5 minutes, yielding up to seven-times the normal concentration of platelets. The system weighs four pounds, making it smaller and portable.